Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05132205 · ClinicalTrials.gov registry record · NA
Radiofrequency Ablation of Papillary Thyroid Microcarcinoma
A NA study of Papillary Thyroid Cancer, sponsored by Johns Hopkins University.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05132205 is a NA study of Papillary Thyroid Cancer that has completed, run by Johns Hopkins University. The registered enrollment target is 10 participants, below the 445-participant average among 6 other Papillary Thyroid Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05132205, a NA study of Papillary Thyroid Cancer, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Traditionally, surgery has been the standard recommendation for treating papillary thyroid cancer. The risk of surgery including permanent hoarseness, permanent hypocalcemia, a mid-cervical scar, and the potential for permanent hypothyroidism may be unacceptable for some patients, especially with low risk papillary thyroid carcinoma. The recent American Thyroid Association guidelines have proposed the option of active surveillance with low risk papillary thyroid cancer less than 210 mm. However, most patients find observation anxiety provoking knowing of having cancer. Radiofrequency ablation (RFA) of small low risk papillary thyroid cancer is a promising therapeutic modality for these patients that reduces the risks associated with surgery and the anxiety of taking a watchful approach. However, this technique has not been validated in the North American population. The investigators aim to describe the investigators' initial experience with RFA of low risk papillary thyroid microcarcinoma (PTMC) compared to active surveillance (AS) done by Head and Neck Endocrine surgeons at Johns Hopkins Medical Institute. Primary objective: * To evaluate the safety, efficacy and oncological outcomes of the procedure. Secondary objective: * To determine the patient functional outcomes in comparison to the observational control.
Conditions Studied
Interventions
- PROCEDURE Radiofrequency Ablation
Study Locations (1)
Maryland
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-12-17 |
| Est. Completion | 2024-11-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05132205
The ClinicalTrials.gov registry entry for NCT05132205 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 6 other Papillary Thyroid Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Papillary Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Radiofrequency Ablation is the first listed.
NCT05132205 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05132205 about?
NCT05132205 is a clinical study titled "Radiofrequency Ablation of Papillary Thyroid Microcarcinoma". Traditionally, surgery has been the standard recommendation for treating papillary thyroid cancer. The risk of surgery including permanent hoarseness, permanent hypocalcemia, a mid-cervical scar, and the potential for permanent hypothyroidism may be unacceptable for some patients, especially with lo...
What is the current status of trial NCT05132205?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2021-12-17. Estimated completion is 2024-11-19.
What conditions does trial NCT05132205 study?
This clinical trial studies the following conditions: Papillary Thyroid Cancer.
What interventions are being tested in trial NCT05132205?
The interventions under investigation include: Radiofrequency Ablation (PROCEDURE).
Who is sponsoring clinical trial NCT05132205?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05132205 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papillary Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
RECRUITING · Phase 2
-
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
RECRUITING
-
Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers
RECRUITING
-
Studies on Tumors of the Thyroid
RECRUITING
-
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
ACTIVE NOT RECRUITING · Phase 1
-
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.